Approval status, evidence type, exact formulation limits, and evidence-review dates. No generic dose or preparation recipes.
| Name | Category | U.S. status | Evidence type | Exact formulation | Reviewed |
|---|---|---|---|---|---|
| Adamax | Cognitive/Neuroprotection | Not FDA-approved. | Unverified compound; related Semax evidence does not transfer | No FDA-approved formulation identified | 2026-09-27 |
| AOD-9604 | Weight loss/Fat metabolism | Not FDA-approved. | Animal studies plus an unpublished/limited human development program | No FDA-approved formulation identified | 2026-09-27 |
| BPC-157 | Recovery | No FDA-approved BPC-157 product | Preclinical studies and small human reports | No FDA-approved formulation identified | 2026-09-28 |
| Cerebrolysin | Cognitive/Neuroprotection | Not FDA-approved. | Systematic review of randomized trials | No FDA-approved formulation identified | 2026-09-27 |
| CJC-1295 and modified GRF | Muscle growth | No FDA-approved CJC-1295 product | Early human hormone studies; formulation matters | No FDA-approved formulation identified | 2026-09-26 |
| Dihexa | Cognitive/Neuroprotection | Not FDA-approved. | Retracted cell/animal research; no established human trial evidence | No FDA-approved formulation identified | 2026-09-27 |
| DSIP | Sleep | Not FDA-approved. | Small historical human studies and narrative review | No FDA-approved formulation identified | 2026-09-27 |
| Epithalon | Longevity/Anti-aging | Not FDA-approved. | Cell-line research and limited non-U.S. literature | No FDA-approved formulation identified | 2026-09-27 |
| GHK-Cu | Skin research | Cosmetic use is not FDA approval. FDA separately flags injectable compounding risks. [6,7] | Limited topical human studies; injection benefits unestablished | No FDA-approved formulation identified | 2026-09-27 |
| IGF-1 LR3 | Muscle growth | No FDA-approved IGF-1 LR3 product | Preclinical evidence | No FDA-approved formulation identified | 2026-09-26 |
| Ipamorelin | Hormone research | Investigational use in the cited studies. [1,2] | Limited human studies; routine benefit unestablished | No FDA-approved formulation identified | 2026-09-27 |
| KLOW blend | Experimental blend | Not FDA-approved. FDA has identified significant safety concerns or major human-data gaps for injectable GHK-Cu, BPC-157, TB-500 and KPV. | No blend-specific clinical evidence | No FDA-approved formulation identified | 2026-09-26 |
| KPV | Recovery/Anti-inflammatory | Not FDA-approved. | Cell and animal research | No FDA-approved formulation identified | 2026-09-27 |
| MOTS-c | Metabolic research | No established clinical treatment in the cited sources. [1–3] | Preclinical treatment evidence | No FDA-approved formulation identified | 2026-09-27 |
| Melanotan II | Pigmentation research | Not approved as a tanning agent in Australia; TGA warns against use. [6] | Small human studies; serious safety concerns | No FDA-approved formulation identified | 2026-09-27 |
| NAD+ | Longevity/Energy | Not FDA-approved. | 2026 systematic review of human NAD-precursor and NAD+ studies | No FDA-approved formulation identified | 2026-09-27 |
| PT-141 | Sexual health | FDA-approved as Vyleesi for a specific HSDD indication | Approved for a defined HSDD population | No FDA-approved formulation identified | 2026-09-26 |
| Retatrutide | Weight loss | Not FDA-approved. | Peer-reviewed Phase 2 plus sponsor-reported Phase 3 topline | No FDA-approved formulation identified | 2026-09-27 |
| Selank | Cognitive/Anxiety | Not FDA-approved. | Small human study against medazepam, not placebo | No FDA-approved formulation identified | 2026-09-27 |
| Semaglutide | Weight loss | FDA-approved only as Ozempic, Wegovy, Wegovy HD and Rybelsus in their labeled indications. | Approved labels and randomized trials | Ozempic, Wegovy, Wegovy HD and Rybelsus in their labeled indications | 2026-09-27 |
| Semax | Cognitive/Neuroprotection | Not FDA-approved. | Small/older clinical studies plus preclinical evidence | No FDA-approved formulation identified | 2026-09-27 |
| Sermorelin | Muscle growth | Not FDA-approved. | Historical approval record and limited clinical studies | No FDA-approved formulation identified | 2026-09-27 |
| Elamipretide | Mitochondrial disease | FDA accelerated approval for Barth syndrome in patients weighing at least 30 kg | FDA accelerated approval for a narrow indication | No FDA-approved formulation identified | 2026-09-26 |
| Survodutide | Weight loss | Not FDA-approved. | Peer-reviewed Phase 3 randomized trial | No FDA-approved formulation identified | 2026-09-27 |
| TB-500 | Recovery | No FDA-approved TB-500 product | Human treatment evidence not established | No FDA-approved formulation identified | 2026-09-26 |
| Tesamorelin | HIV-associated lipodystrophy | FDA-approved as Egrifta for adults with HIV-associated lipodystrophy | Approved for HIV-associated lipodystrophy | No FDA-approved formulation identified | 2026-09-26 |
| Tirzepatide | Weight loss | FDA-approved only as Mounjaro and Zepbound in their labeled indications. | Approved labels and randomized head-to-head trial | Mounjaro and Zepbound in their labeled indications | 2026-09-27 |
← Browse all profiles | Prescription arithmetic →
vialprep research · Sources: PubMed, FDA, peer-reviewed trials · How we verify